Share chart Geron Corporation
Extended chart
Simple chart
About Geron Corporation
Корпорация "Герон", клиническая биофармацевтическая компания на поздней стадии, специализируется на разработке и коммерциализации методов лечения гематологических миелоидных злокачественных новообразований. Он обладает правами на иметелстат, ингибитор теломеразы в клинических испытаниях фазы 2F3, который ингибирует неконтролируемую пролиферацию злокачественных клеток-предшественников при гематологических миелоидных злокачественных опухолях, чтобы уменьшить дисфункциональную продукцию клеток крови и обеспечить восстановление нормальной продукции клеток крови. more details| IPO date | 1996-06-30 |
|---|---|
| ISIN | US3741631036 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://www.geron.com |
| Цена ао | 1.7 |
| Change price per day: | +6.15% (1.3) |
|---|---|
| Change price per week: | +0% (1.38) |
| Change price per month: | -22.03% (1.77) |
| Change price per 3 month: | -56.47% (3.17) |
| Change price per half year: | -66.67% (4.14) |
| Change price per year: | -62.09% (3.64) |
| Change price per 3 year: | -5.48% (1.46) |
| Change price per 5 year: | +15% (1.2) |
| Change price per year to date: | -64.89% (3.93) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| RA Capital Management, L.P. | 46202425 | 8.45 |
| Blackrock Inc. | 42172679 | 7.71 |
| Deep Track Capital, LP | 29583449 | 5.41 |
| Vanguard Group Inc | 28564574 | 5.22 |
| State Street Corporation | 25625606 | 4.69 |
| Vivo Capital, LLC | 24143681 | 4.41 |
| Tcg Crossover Management, Llc | 23375839 | 4.27 |
| NEA Management Company, LLC | 22776409 | 4.16 |
| Millennium Management LLC | 14730986 | 2.69 |
| Geode Capital Management, LLC | 10943649 | 2 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Future Tech ETF | 0.27625 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.27625 | 618.5 | 0.8416 |
| iShares Morningstar Small-Cap Growth ETF | 0.10126 | 596.94 | 0.72598 |
| iShares Morningstar Small-Cap ETF | 0.0513 | 391.25 | 1.60498 |
| 0.18 | 508.26 | 1 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Ms. Melissa A. Kelly Behrs | Executive VP of Business Operations & Chief Alliance Officer | 753.22k | 1964 (61 year) |
| Ms. Shannon Odam | Senior VP & Chief People Officer | N/A | 1975 (50 years) |
| Mr. Edward E. Koval | Executive VP & Chief Business Officer | N/A | 1962 (63 years) |
| Dr. John A. Scarlett M.D. | Chairman of the Board, President & CEO | 1.53M | 1951 (74 years) |
| Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | N/A | |
| Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer | N/A | 1983 (42 years) |
| Ms. Michelle J. Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | N/A | 1967 (58 years) |
| Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO | 847.2k | 1964 (61 year) |
| Mr. Scott Samuels | Executive VP, Chief Legal Officer & Secretary | ||
| Mr. James Ziegler M.B.A. | Executive VP & Chief Commercial Officer |
Address: United States, Foster City, 919 East Hillsdale Boulevard - open in Google maps, open in Yandex maps
Website: http://www.geron.com
Website: http://www.geron.com
